Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX) is a biotechnology company centered on DehydraTECH™, a patented oral drug delivery formulation and processing platform. Company news releases highlight ongoing research and development programs where DehydraTECH is evaluated with active pharmaceutical ingredients such as GLP-1 drugs and cannabidiol (CBD), as well as updates on licensing, partnerships and capital markets activity.
Investors following LEXX news can expect detailed coverage of clinical and preclinical study results, particularly in the GLP-1 sector. Recent announcements describe human pilot studies and a registered Phase 1b study in Australia that compare DehydraTECH-based oral formulations of semaglutide, tirzepatide and liraglutide against existing injectable or oral reference products. These updates often include information on safety, tolerability, adverse events, blood glucose and HbA1c changes, body weight, biodistribution and blood pressure outcomes.
Lexaria’s news flow also includes strategic and business development updates, such as the extension of a Material Transfer Agreement with a pharmaceutical company evaluating DehydraTECH, the engagement of a global life science business development advisory firm, and commentary on how new data sets are being used to guide future R&D plans. In addition, the company regularly reports on financing transactions via registered direct offerings and private placements, describing how proceeds are intended to support research, working capital and general corporate purposes.
For readers tracking LEXX, this news page provides a centralized view of the company’s scientific progress, intellectual property developments, partnership discussions and funding activities related to its DehydraTECH platform.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Lexaria Bioscience Corp. has selected InClin, a California-based CRO, to manage its upcoming Phase 1b hypertension study, titled HYPER-H23-1, evaluating the safety and efficacy of its patented DehydraTECH-CBD. The study aims to assess the treatment on 120 patients with Stage 1 and Stage 2 hypertension, following successful FDA pre-IND meeting outcomes. Lexaria plans to file its IND application this summer, anticipating FDA authorization within 60 days. Previous studies indicated that DehydraTECH-CBD significantly reduced blood pressure with no serious adverse events, setting it apart from other CBD formulations. The company is also working on the necessary stability testing for its drug product, which is crucial for the IND submission.
Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) has announced the receipt of four new patents, enhancing its intellectual property portfolio globally. In Japan, a patent for Stable Ready-to-Drink Beverage Compositions marks the 5th awarded in the country; in Australia, a patent for Enhanced Delivery of Antiviral Agents becomes the 10th. Canada has allowed a patent for Nicotine Compounds, and the USA has granted a patent for Treating Hypertension, crucial for future FDA applications. These patents underscore Lexaria's commitment to expanding its DehydraTECH technology, vital in the lucrative cardiovascular drugs market projected to grow from US$146.5 billion in 2022 to $173.5 billion by 2026. With these additions, Lexaria's patent portfolio increases to 32 granted patents worldwide.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) has completed its diabetes study DIAB-A22-1, demonstrating significant positive effects of DehydraTECH-CBD on obese diabetic rats. Key outcomes include:
- Approximately 7% weight loss over 8 weeks, with treated animals losing weight while untreated animals gained weight.
- Improved metabolic function indicated by stable food and water intake despite weight loss.
- Significant reductions in triglyceride levels, with the lower dose achieving over 25% reduction compared to untreated rats.
- Potential enhancement of activity levels at lower doses of DehydraTECH-CBD.
These findings encourage further investigation into using DehydraTECH-CBD for diabetes treatment.